瑜欣電子(301107.SZ):擬200萬元認購共青城臨雲精選十二號股權投資合夥企業
格隆匯8月23日丨瑜欣電子(301107.SZ)公佈,為提高公司閒置資金使用效率,規劃更廣泛的產業領域,公司擬使用自有資金200萬元認購標的基金份額,成為共青城臨雲精選十二號股權投資合夥企業(有限合夥)(簡稱“標的基金”)的有限合夥人,公司擬簽署《共青城臨雲精選十二號股權投資合夥企業(有限合夥)之有限合夥協議》,該標的基金的管理人為重慶臨雲股權投資基金管理有限公司(簡稱“臨雲投資”)。
標的基金直接投資於成都星聯芯通科技有限公司(統一社會信用代碼:91510100331925075E)股權;全國中小企業股份轉讓系統(新三板)創新層掛牌公司股份及其增發的股份。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.